CAS 2591-17-5|D-Luciferin
Introduction：Basic information about CAS 2591-17-5|D-Luciferin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | D-Luciferin | ||
|---|---|---|---|
| CAS Number | 2591-17-5 | Molecular Weight | 280.323 |
| Density | 1.8±0.1 g/cm3 | Boiling Point | 587.6±60.0 °C at 760 mmHg |
| Molecular Formula | C11H8N2O3S2 | Melting Point | 200-204ºC |
| MSDS | ChineseUSA | Flash Point | 309.2±32.9 °C |
Names
| Name | Photinus luciferin |
|---|---|
| Synonym | More Synonyms |
D-Luciferin BiologicalActivity
| Description | D-luciferin is the natural substrate of luciferases that catalyze the production of light in bioluminescent insects. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersDye ReagentsNatural Products >>OthersResearch Areas >>Others |
| In Vitro | D-luciferin is the natural substrate of the enzyme luciferase (Luc), that catalyzes the production of the typical yellowgreen light of fireflies.The present review covers the synthesis of D-luciferin and derivatives or analogues that are substrates or inhibitors of the luciferase from the American firefly Photinus pyralis, the enzyme more frequently used in techniques of in vitro and optical imaging[1]. |
| In Vivo | Bioluminescence imaging (BLI) using the firefly luciferase (Fluc) as a reporter gene and D-luciferin as a substrate is currently the most widely employed technique. The total signal intensity is plotted against the time after D-luciferin injection to generate a time-intensity curve. In addition to the peak signal, the signals at fixed time points (5, 10, 15, and 20 min) after D-luciferin injection are determined as alternatives to the peak signal. The signal in a given time-intensity curve is normalized for the peak signal in the curve to represent the pattern of temporal changes after D-luciferin injection[2]. |
| Animal Admin | Mice[2] In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10, 12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferin in 100 μL of phosphate-buffered saline subcutaneously near the scapula and were placed in the light-tight chamber of the imaging system under isoflurane anesthesia. Beginning 5 min after injection, dorsal luminescent images with an exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferin injection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because of the prolonged time course of light emission. Binning is 4 and the field of view is 15 cm. |
| References | [1]. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009 (i) 265-288. [2]. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growthusing in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408. |
Chemical & Physical Properties
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Boiling Point | 587.6±60.0 °C at 760 mmHg |
| Melting Point | 200-204ºC |
| Molecular Formula | C11H8N2O3S2 |
| Molecular Weight | 280.323 |
| Flash Point | 309.2±32.9 °C |
| Exact Mass | 279.997620 |
| PSA | 136.32000 |
| LogP | 0.87 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.865 |
| InChIKey | BJGNCJDXODQBOB-SSDOTTSWSA-N |
| SMILES | O=C(O)C1CSC(c2nc3ccc(O)cc3s2)=N1 |
| Storage condition | -20°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36/37/39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2934999090 |
Customs
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles350
More Articles| PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE 9(10) , e109427, (2014) Immunology-based interventions have been proposed as a promising curative chance to effectively attack postoperative minimal residual disease and distant metastatic localizations of prostate tumors. W... | |
| Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells. Biomaterials 42 , 42-51, (2014) A major limitation in the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer, is delivery of therapeutics to invading tumor cells outside of the area that is safe for sur... | |
| Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget 6 , 15077-94, (2015) The most abundant populations of non-neoplastic cells in the glioblastoma (GBM) microenvironment are resident microglia, macrophages and infiltrating monocytes from the blood circulation. The mechanis... |
Synonyms
| D-Leciferin |
| nbsp |
| D-LUCIFERIN FIREFLY |
| BEETLE LUCIFERIN |
| (S)-4,5-Dihydro-2-(6-hydroxy-1,3-benzothiazol-2-yl)thiazole-4-carboxylic acid |
| D-Luciferin |
| (4S)-2-(6-Hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid |
| 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-, (4S)- |
| D-(-)-Luciferin |
| LUCIFERIN |
| EINECS 219-981-3 |
| (S)-2-(6-Hydroxy-2-benzothiazolyl)-2-thiazoline-4-carboxylic Acid |
| firefly liciferin |
| Firefly luciferin |
| MFCD00042929 |
| (S)-4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylicacid |
| (S)-2-(6-Hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid |
| AURORA KA-6717 |
| 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-, (S)- |
| firefly luciferin IV |
| (S)-luciferin |
| LUCIFERIN,D |
